CR20140368A - Derivados y composiciones de isoindol 4´-0-sustituidos, composiciones que las comprenden y metodos de uso de los mismos (divisional 11036) - Google Patents
Derivados y composiciones de isoindol 4´-0-sustituidos, composiciones que las comprenden y metodos de uso de los mismos (divisional 11036)Info
- Publication number
- CR20140368A CR20140368A CR20140368A CR20140368A CR20140368A CR 20140368 A CR20140368 A CR 20140368A CR 20140368 A CR20140368 A CR 20140368A CR 20140368 A CR20140368 A CR 20140368A CR 20140368 A CR20140368 A CR 20140368A
- Authority
- CR
- Costa Rica
- Prior art keywords
- compositions
- methods
- isoindol
- divisional
- substitutes
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/4035—Isoindoles, e.g. phthalimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Heart & Thoracic Surgery (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Anesthesiology (AREA)
- Rheumatology (AREA)
- AIDS & HIV (AREA)
- Molecular Biology (AREA)
- Ophthalmology & Optometry (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Psychiatry (AREA)
Abstract
Se proporcionan compuestos de isoindolina 4´-Osustituida de la fórmula (1), y sales farmacéuticamente aceptables, solvatos, clatratos, estereoisómeros y profármacos de los mismos. Se describen métodos de uso y composiciones farmacéuticas de estos compuestos.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US91932307P | 2007-03-20 | 2007-03-20 |
Publications (1)
Publication Number | Publication Date |
---|---|
CR20140368A true CR20140368A (es) | 2014-08-25 |
Family
ID=39719168
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CR11036A CR11036A (es) | 2007-03-20 | 2009-09-21 | Derivados y composiciones de isoindol 4' -o- sustituidos, composiciones que las comprenden y metodos de uso de los mismos |
CR20140368A CR20140368A (es) | 2007-03-20 | 2014-08-01 | Derivados y composiciones de isoindol 4´-0-sustituidos, composiciones que las comprenden y metodos de uso de los mismos (divisional 11036) |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CR11036A CR11036A (es) | 2007-03-20 | 2009-09-21 | Derivados y composiciones de isoindol 4' -o- sustituidos, composiciones que las comprenden y metodos de uso de los mismos |
Country Status (25)
Country | Link |
---|---|
US (6) | US8153659B2 (es) |
EP (2) | EP3101017B1 (es) |
JP (4) | JP2010522170A (es) |
KR (3) | KR20090121400A (es) |
CN (2) | CN103641814A (es) |
AR (1) | AR065810A1 (es) |
AU (1) | AU2008229383B2 (es) |
BR (1) | BRPI0809011A8 (es) |
CA (1) | CA2681633C (es) |
CL (1) | CL2008000805A1 (es) |
CO (1) | CO6231033A2 (es) |
CR (2) | CR11036A (es) |
EC (1) | ECSP099663A (es) |
ES (2) | ES2601131T3 (es) |
IL (1) | IL200990A (es) |
MX (1) | MX2009010082A (es) |
MY (1) | MY180812A (es) |
NI (1) | NI200900170A (es) |
NZ (2) | NZ579890A (es) |
PE (1) | PE20081894A1 (es) |
RU (1) | RU2471794C2 (es) |
UA (1) | UA97976C2 (es) |
UY (1) | UY30977A1 (es) |
WO (1) | WO2008115516A2 (es) |
ZA (1) | ZA200906497B (es) |
Families Citing this family (64)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2929331B2 (ja) * | 1990-07-18 | 1999-08-03 | 丸善石油化学株式会社 | トラクションドライブ用流体 |
AU2005311888A1 (en) * | 2004-12-01 | 2006-06-08 | Celgene Corporation | Compositions comprising immunomodulatory compounds and the use thereof for the treatment of immunodeficiency disorders |
BRPI0809011A8 (pt) * | 2007-03-20 | 2019-01-15 | Celgene Corp | composto, composição farmacêutica, método de tratamento, controle ou prevenção de uma doença ou distúrbio, e, forma de dosagem unitária única |
WO2009085234A2 (en) * | 2007-12-20 | 2009-07-09 | Signal Pharmaceuticals, Inc. | Use of micro-rna as a biomarker of immunomodulatory drug activity |
WO2011072275A2 (en) | 2009-12-11 | 2011-06-16 | Nono, Inc. | Agents and methods for treating ischemic and other diseases |
ES2713482T3 (es) * | 2010-02-11 | 2019-05-22 | Celgene Corp | Derivados de arilmetoxi isoindolina y composiciones que los comprenden y métodos de uso de los mismos |
AU2013245487B2 (en) * | 2010-02-11 | 2016-03-10 | Celgene Corporation | Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same |
AU2016203826B2 (en) * | 2010-02-11 | 2018-05-17 | Celgene Corporation | Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same |
CA2867134C (en) * | 2011-03-28 | 2019-05-07 | Sheila Dewitt | 2',6'-dioxo-3'-deutero-piperdin-3-yl-isoindoline compounds |
EP2720695A4 (en) * | 2011-06-15 | 2014-11-12 | Nono Inc | ACTIVE AGENTS AND METHODS FOR TREATING ISCHEMIC AND OTHER DISEASES |
CN102731851B (zh) * | 2012-06-28 | 2013-11-27 | 芜湖宏达橡塑阀门制造有限公司 | 一种耐油橡胶 |
CN102731850B (zh) * | 2012-06-28 | 2013-11-27 | 芜湖宏达橡塑阀门制造有限公司 | 耐油耐磨橡胶 |
CN102731853B (zh) * | 2012-06-28 | 2013-11-27 | 芜湖宏达橡塑阀门制造有限公司 | 耐油橡胶 |
US9133161B2 (en) * | 2012-07-27 | 2015-09-15 | Celgene Corporation | Processes for preparing isoindoline-1,3-dione compounds |
US20150038511A1 (en) | 2012-08-09 | 2015-02-05 | Celgene Corporation | Treatment of immune-related and inflammatory diseases |
EP3466942B1 (en) | 2012-08-09 | 2022-04-20 | Celgene Corporation | Processes for the preparation of (s)-3-4-((4-(morpholinomethyl) benzyl)oxy)-1-oxoisoindolin-2-yl) piperidine-2,6-dione and pharmaceutically acceptable forms thereof |
UA116992C2 (uk) | 2012-08-09 | 2018-06-11 | Селджин Корпорейшн | Лікування імуноопосередкованого захворювання (варіанти) |
AU2013299627C1 (en) * | 2012-08-09 | 2018-05-31 | Celgene Corporation | Methods of treating cancer using 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione |
WO2014110558A1 (en) | 2013-01-14 | 2014-07-17 | Deuterx, Llc | 3-(5-substituted-4-oxoquinazolin-3(4h)-yl)-3-deutero-piperidine-2,6-dione derivatives |
US9695145B2 (en) | 2013-01-22 | 2017-07-04 | Celgene Corporation | Processes for the preparation of isotopologues of 3-(4-((4- morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and pharmaceutically acceptable salts thereof |
US9242966B2 (en) | 2013-03-11 | 2016-01-26 | Bristol-Myers Squibb Company | Phthalazines as potassium ion channel inhibitors |
CA2941560A1 (en) | 2013-03-14 | 2014-09-25 | Deuterx, Llc | 3-(substituted-4-oxo-quinazolin-3(4h)-yl)-3-deutero-piperidine-2,6-dione derivatives |
JP6389241B2 (ja) | 2013-04-17 | 2018-09-12 | シグナル ファーマシューティカルズ,エルエルシー | 癌を治療するためのTORキナーゼ阻害剤及びIMiD化合物を含む組合せ療法 |
UA117141C2 (uk) | 2013-10-08 | 2018-06-25 | Селджин Корпорейшн | Склади (s)-3-(4-((4-(морфолінометил)бензил)оксі)-1-оксоізоіндолін-2-іл)піперидин-2,6-діону |
JP2017522270A (ja) | 2014-05-19 | 2017-08-10 | セルジーン コーポレイション | 全身性エリテマトーデスの治療のための3−(4−((4−(モルホリノメチル−ベンジル)オキシ)−1−オキソイソインドリン−2−イル)ピペリジン−2,6−ジオン |
PT3214081T (pt) * | 2014-10-30 | 2020-08-31 | Kangpu Biopharmaceuticals Ltd | Derivado de isoindolina, seu intermediário, seu método de preparação, sua composição farmacêutica e sua utilização |
US9809603B1 (en) | 2015-08-18 | 2017-11-07 | Deuterx, Llc | Deuterium-enriched isoindolinonyl-piperidinonyl conjugates and oxoquinazolin-3(4H)-yl-piperidinonyl conjugates and methods of treating medical disorders using same |
US10159665B2 (en) | 2016-03-23 | 2018-12-25 | Louis Habash | Preventing amyloid plaque formation by treating a human subject with a nitroxide |
US20180078539A1 (en) | 2016-03-23 | 2018-03-22 | Louis Habash | T-cell regulation in t-cell mediated diseases by reducing pathogenic function of th17 in a human subject through treatment with a nitroxide |
CA3056059C (en) * | 2016-03-23 | 2023-02-14 | Louis Habash | Increasing expression level of apoptosis-related genes by treating a human subject with a nitroxide |
US10231959B2 (en) | 2016-03-23 | 2019-03-19 | Louis Habash | Increasing expression level of apoptosis-related genes by treating a human subject with a nitroxide |
CN109562107A (zh) | 2016-05-10 | 2019-04-02 | C4医药公司 | 用于靶蛋白降解的杂环降解决定子体 |
WO2017197051A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | Amine-linked c3-glutarimide degronimers for target protein degradation |
CN109562113A (zh) | 2016-05-10 | 2019-04-02 | C4医药公司 | 用于靶蛋白降解的螺环降解决定子体 |
EP3455218A4 (en) | 2016-05-10 | 2019-12-18 | C4 Therapeutics, Inc. | C3 CARBON-BASED GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN REDUCTION |
KR20220028178A (ko) | 2016-12-16 | 2022-03-08 | 강푸 바이오파마슈티칼즈 리미티드 | 조성물, 이의 적용 및 치료 방법 |
CN118440096A (zh) | 2017-06-20 | 2024-08-06 | C4医药公司 | 用于蛋白降解的n/o-连接的降解决定子和降解决定子体 |
JP7258009B2 (ja) | 2017-07-10 | 2023-04-14 | セルジーン コーポレイション | 抗増殖化合物及びその使用方法 |
CN118206529A (zh) | 2017-09-04 | 2024-06-18 | C4医药公司 | 二氢苯并咪唑酮 |
CN111278816B (zh) | 2017-09-04 | 2024-03-15 | C4医药公司 | 二氢喹啉酮 |
WO2019043214A1 (en) | 2017-09-04 | 2019-03-07 | F. Hoffmann-La Roche Ag | glutarimide |
EP3710002A4 (en) | 2017-11-16 | 2021-07-07 | C4 Therapeutics, Inc. | DEGRADER AND DEGRONE FOR TARGETED PROTEIN DEGRADATION |
WO2019191112A1 (en) | 2018-03-26 | 2019-10-03 | C4 Therapeutics, Inc. | Cereblon binders for the degradation of ikaros |
AU2019251151B2 (en) * | 2018-04-09 | 2022-07-07 | Shanghaitech University | Target protein degradation compounds, their anti-tumor use, their intermediates and use of intermediates |
EP3781156A4 (en) | 2018-04-16 | 2022-05-18 | C4 Therapeutics, Inc. | SPIROCYCLIC COMPOUNDS |
FI3784663T3 (fi) | 2018-04-23 | 2023-10-06 | Celgene Corp | Substituoituja 4-aminoisoindoliini-1,3-dioniyhdisteitä ja niiden käyttö lymfooman hoitamiseksi |
EP3578561A1 (en) | 2018-06-04 | 2019-12-11 | F. Hoffmann-La Roche AG | Spiro compounds |
HUE063715T2 (hu) * | 2018-07-10 | 2024-01-28 | Novartis Ag | 3-(5-hidroxi-1-oxoizoindolin-2-il)piperidin-2,6-dion származékok és alkalmazásuk ikaros család cinkujj-2 (IKZF2)-függõ betegségek kezelésében |
JP7168773B2 (ja) * | 2018-09-30 | 2022-11-09 | 上海 インスティテュート オブ マテリア メディカ、チャイニーズ アカデミー オブ サイエンシーズ | イソインドリン化合物、その調製方法、医薬組成物および使用 |
EP3860610A4 (en) | 2018-10-01 | 2022-06-15 | Celgene Corporation | POLYTHERAPY FOR THE TREATMENT OF CANCER |
US20220001018A1 (en) * | 2018-11-01 | 2022-01-06 | Northwestern University | Targeting pleckstrin-2 for treating cancer |
CA3122317C (en) | 2018-12-06 | 2023-10-03 | Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences | Isoindoline compound, and preparation method, pharmaceutical composition, and application of isoindoline compound |
FI3962489T3 (fi) * | 2019-02-22 | 2023-06-09 | Elkem Silicones Usa Corp | Lääkeaineen antamiseen tarkoitettu silikonikoostumus vaikuttavan aineen eluution parantamiseksi |
CN111747924B (zh) * | 2019-03-29 | 2023-11-10 | 华东师范大学 | 一类来那度胺/泊马度胺类似物及其应用 |
CN113677664A (zh) | 2019-04-12 | 2021-11-19 | C4医药公司 | Ikaros和aiolos的三环降解物 |
KR20220016049A (ko) * | 2019-05-31 | 2022-02-08 | 스촨 하이스코 파마수티컬 씨오., 엘티디 | Btk 억제제 고리 유도체, 이의 제조 방법 및 이의 약제학적 응용 |
CA3169011A1 (en) * | 2020-02-25 | 2021-09-02 | Xiaobao Yang | Glutarimide skeleton-based compounds and uses thereof |
JP2023523545A (ja) * | 2020-04-17 | 2023-06-06 | エサイエント ファーマシューティカルズ,インコーポレイティド | Mas関連Gタンパク質受容体X4のモジュレーター、関連製品及びその使用方法 |
KR20230042057A (ko) | 2020-07-20 | 2023-03-27 | 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 | 황-함유 이소인돌린 유도체, 및 이의 제조 방법 및 이의 의학적 용도 |
TW202241872A (zh) * | 2021-01-05 | 2022-11-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | 稠雜環基取代的環己二醯亞胺衍生物、其製備方法及其在醫藥上的應用 |
CA3208313A1 (en) | 2021-01-13 | 2022-07-21 | Monte Rosa Therapeutics Ag | Isoindolinone compounds |
CN115504963A (zh) * | 2021-06-22 | 2022-12-23 | 苏州开拓药业股份有限公司 | 一种c-Myc蛋白降解剂 |
AU2023210002A1 (en) | 2022-01-19 | 2024-08-22 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Crystalline form of sulfur-containing isoindoline derivative |
US20240208937A1 (en) * | 2022-11-04 | 2024-06-27 | Bristol-Myers Squibb Company | Compounds and Their Use for Treatment of Hemoglobinopathies |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5001116A (en) | 1982-12-20 | 1991-03-19 | The Children's Medical Center Corporation | Inhibition of angiogenesis |
US4994443A (en) | 1982-12-20 | 1991-02-19 | The Children's Medical Center Corporation | Inhibition of angiogenesis |
US5800819A (en) | 1996-01-25 | 1998-09-01 | National Institute For Pharmaceutical Research And Development Federal Ministry Of Science And Technology | Piper guineense, pterocarpus osun, eugenia caryophyllata, and sorghum bicolor extracts for treating sickle cell disease |
KR19980074060A (ko) * | 1997-03-21 | 1998-11-05 | 김윤배 | 신규한 치환된 3,4-디알콕시페닐 유도체 |
AU745884B2 (en) * | 1998-03-16 | 2002-04-11 | Celgene Corporation | 2-(2,6-dioxopiperidin-3-yl)isoindoline derivatives, their preparation and their use as inhibitors of inflammatory cytokines |
US6458810B1 (en) * | 2000-11-14 | 2002-10-01 | George Muller | Pharmaceutically active isoindoline derivatives |
US20030045552A1 (en) * | 2000-12-27 | 2003-03-06 | Robarge Michael J. | Isoindole-imide compounds, compositions, and uses thereof |
US7320992B2 (en) * | 2003-08-25 | 2008-01-22 | Amgen Inc. | Substituted 2,3-dihydro-1h-isoindol-1-one derivatives and methods of use |
BRPI0414497A (pt) * | 2003-09-17 | 2006-11-14 | Us Gov Health & Human Serv | análogos de talidomida |
GB0324790D0 (en) * | 2003-10-24 | 2003-11-26 | Astrazeneca Ab | Amide derivatives |
AU2005311888A1 (en) | 2004-12-01 | 2006-06-08 | Celgene Corporation | Compositions comprising immunomodulatory compounds and the use thereof for the treatment of immunodeficiency disorders |
WO2006067444A1 (en) * | 2004-12-24 | 2006-06-29 | Astrazeneca Ab | Amide derivatives |
BRPI0809011A8 (pt) * | 2007-03-20 | 2019-01-15 | Celgene Corp | composto, composição farmacêutica, método de tratamento, controle ou prevenção de uma doença ou distúrbio, e, forma de dosagem unitária única |
-
2008
- 2008-03-19 BR BRPI0809011A patent/BRPI0809011A8/pt not_active Application Discontinuation
- 2008-03-19 NZ NZ579890A patent/NZ579890A/en not_active IP Right Cessation
- 2008-03-19 CN CN201310547773.7A patent/CN103641814A/zh active Pending
- 2008-03-19 NZ NZ599199A patent/NZ599199A/xx not_active IP Right Cessation
- 2008-03-19 ES ES08726977.5T patent/ES2601131T3/es active Active
- 2008-03-19 RU RU2009138500/04A patent/RU2471794C2/ru active
- 2008-03-19 KR KR1020097021797A patent/KR20090121400A/ko active Application Filing
- 2008-03-19 CN CN200880016715A patent/CN101679380A/zh active Pending
- 2008-03-19 CA CA2681633A patent/CA2681633C/en active Active
- 2008-03-19 EP EP16170365.7A patent/EP3101017B1/en active Active
- 2008-03-19 KR KR1020157009558A patent/KR101791757B1/ko active IP Right Grant
- 2008-03-19 US US12/077,715 patent/US8153659B2/en active Active
- 2008-03-19 EP EP08726977.5A patent/EP2142534B1/en active Active
- 2008-03-19 UA UAA200910592A patent/UA97976C2/ru unknown
- 2008-03-19 MY MYPI20093935A patent/MY180812A/en unknown
- 2008-03-19 AR ARP080101179A patent/AR065810A1/es not_active Application Discontinuation
- 2008-03-19 WO PCT/US2008/003602 patent/WO2008115516A2/en active Application Filing
- 2008-03-19 KR KR1020177021704A patent/KR20170093996A/ko not_active Application Discontinuation
- 2008-03-19 JP JP2009554563A patent/JP2010522170A/ja not_active Withdrawn
- 2008-03-19 ES ES16170365T patent/ES2734253T3/es active Active
- 2008-03-19 AU AU2008229383A patent/AU2008229383B2/en active Active
- 2008-03-19 MX MX2009010082A patent/MX2009010082A/es active IP Right Grant
- 2008-03-20 CL CL2008000805A patent/CL2008000805A1/es unknown
- 2008-03-24 UY UY30977A patent/UY30977A1/es not_active Application Discontinuation
- 2008-03-24 PE PE2008000525A patent/PE20081894A1/es not_active Application Discontinuation
-
2009
- 2009-09-16 IL IL200990A patent/IL200990A/en not_active IP Right Cessation
- 2009-09-17 ZA ZA2009/06497A patent/ZA200906497B/en unknown
- 2009-09-18 NI NI200900170A patent/NI200900170A/es unknown
- 2009-09-21 CR CR11036A patent/CR11036A/es unknown
- 2009-09-30 EC EC2009009663A patent/ECSP099663A/es unknown
- 2009-09-30 CO CO09106869A patent/CO6231033A2/es not_active Application Discontinuation
-
2012
- 2012-03-01 US US13/410,216 patent/US8614328B2/en not_active Ceased
-
2013
- 2013-11-18 US US14/083,205 patent/US9181216B2/en active Active
-
2014
- 2014-06-25 JP JP2014129790A patent/JP5927241B2/ja active Active
- 2014-07-16 US US14/333,454 patent/USRE46639E1/en active Active
- 2014-08-01 CR CR20140368A patent/CR20140368A/es unknown
-
2015
- 2015-10-02 US US14/874,318 patent/US9920027B2/en active Active
- 2015-10-28 JP JP2015211991A patent/JP6373818B2/ja active Active
-
2017
- 2017-08-10 JP JP2017155657A patent/JP6448726B2/ja active Active
-
2018
- 2018-02-02 US US15/887,838 patent/US10385037B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CR20140368A (es) | Derivados y composiciones de isoindol 4´-0-sustituidos, composiciones que las comprenden y metodos de uso de los mismos (divisional 11036) | |
ECSP10010724A (es) | Compuestos de isoindol 5-sustituidos | |
NI201000041A (es) | Derivados y composiciones que comprenden quinazolinona 6-, 7-, u 8 - sustituida y métodos para utilizar la misma. | |
NI200900040A (es) | Derivados de quinazolinona 5-substituidos como agentes antitumorales. | |
NI200900031A (es) | Compuestos de n-metilaminometil isoindol y composiciones que los comprenden y métodos para usar los mismos. | |
DOP2006000193A (es) | Compuestos de isoindol-imida y composiciones que los incluye y metodos para su uso | |
NI201200132A (es) | Derivados de arilmetoxi isoindolina y composiciones que los comprenden y metodos para utilizar los mismos | |
UY30498A1 (es) | Nueva clase de compuestos de benzimidazolilo, sus sales, composiciones farmacéuticas conteniéndolos y aplicaciones | |
CR10710A (es) | Determinadas amidas sustituidas, metodo de elaboracion y metodo de uso de las mismas | |
CR11750A (es) | Pirimidin-5-carboxamidas sustituidas 281 | |
AR047070A1 (es) | Derivados de difenilazetidona | |
UY27516A1 (es) | Bencimidazoles | |
AR028810A1 (es) | Derivados de arilpiperazinil-ciclohexil indol, composiciones farmaceuticas que los comprenden y el uso de los mismos para la manufactura de medicamentos para el tratamiento de la depresion | |
CL2003002770A1 (es) | Compuestos derivados de pirrol e imiddazol; composiciones farmaceuticas que los contienen; procedimiento de preparacion; y su uso en el tratamiento y/o prevencion de enfermedades que estan asociadas con la modulacion de los receptores a canabinoides | |
PA8580301A1 (es) | Nuevos derivados de benzoimidazol utiles como agentes antiproliferativos | |
UY30460A1 (es) | Compuestos terapéuticos | |
UY27685A1 (es) | Indolil-urea derivados de tienopiridinas útiles como agentes antiangiogénicos, y procedimientos para su uso | |
ECSP099442A (es) | Derivados de heteroaril-pirrolidinil- y -piperidinil-cetona | |
CR9391A (es) | Derivados de indanil-piperazinas, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen | |
ECSP088270A (es) | Derivados de (indol-3-il)-heterociclo como agonistas del receptor cannabinoide cb1 | |
UY27980A1 (es) | Indoles 2,7-sustituidos | |
CR11584A (es) | Derivados de oxindol sustituidos y uso de los mismos para el tratamiento de enfermedades dependientes de la vasopresina | |
ATE465151T1 (de) | 4-aryloxy-chinolin-derivate als 5-ht6-modulatoren | |
AR061740A1 (es) | Nuevos derivados naftalenicos, su procedimiento de praparacion y las composiciones farmaceuticas que los contienen | |
ATE246174T1 (de) | Tosylprolin-derivate als thymidylat-synthase inhibitoren |